Showing results (2061-2070 of 2,238) with videos related to
Sort By:
Pageof 224
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Lung Cancer (Amsterdam, Netherlands)|December 9, 2025
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA studyLin Wu, Junling Li, Chong-Rui Xu, et al.Veterinary Parasitology|March 23, 2010
The preparation of neem oil microemulsion (Azadirachta indica) and the comparison of acaricidal time between neem oil microemulsion and other formulations in vitroJiao Xu, Qiao-Jia Fan, Zhong-Qiong Yin, et al.Translational Lung Cancer Research|May 9, 2022
Identification of heritable rare variants associated with early-stage lung adenocarcinoma riskRui Fu, Jia-Tao Zhang, Rong-Rong Chen, et al.Lung Cancer (Amsterdam, Netherlands)|December 6, 2022
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalChan-Yuan Zhang, Hao Sun, Jun-Wei Su, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2018
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor OsimertinibQi Zhang, Xu-Chao Zhang, Jin-Ji Yang, et al.NPJ Digital Medicine|November 18, 2025
Quantifying Early-Stage Lung Adenocarcinoma Progression with a Radiomic TrajectoryZhen-Bin Qiu, Jiaqi Li, Shihua Dou, et al.Targeted Oncology|March 11, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Pageof 224